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Abstract  
L-DOPA is the primary pharmacological treatment for relief of the motor symptoms of 
ParkinsonÕs disease. With prolonged treatment (≥5 years) the majority of patients will 
develop abnormal involuntary movements as a result of L-DOPA treatment, known as L-
DOPA-induced dyskinesia.  Understanding the underlying mechanisms of dyskinesia is a 
crucial step towards developing treatments for this debilitating side effect. We used the 6-
OHDA rat model of ParkinsonÕs disease treated with a three week dosing regimen of L-
DOPA plus the dopa decarboxylase inhibitor benserazide (4 mg/kg and 7.5 mg/kg s.c., 
respectively) to induce dyskinesia in 50% of individuals.  We then used RNA-seq to 
investigate the differences in mRNA expression in the striatum of dyskinetic animals, non-
dyskinetic animals, and untreated parkinsonian controls at the peak of dyskinesia expression, 
60 minutes after L-DOPA administration.  Overall, 255 genes were differentially expressed; 
with significant differences in mRNA expression observed between all three groups. In 
dyskinetic animals 129 genes were more highly expressed and 14 less highly expressed when 
compared with non-dyskinetic and untreated parkinsonian controls. In L-DOPA treated 
animals 42 genes were more highly expressed and 95 less highly expressed when compared 
with untreated parkinsonian controls. Gene set cluster analysis revealed an increase in 
expression of genes associated with the cytoskeleton and phosphoproteins in dyskinetic 
animals compared with non-dyskinetic animals, which is consistent with recent studies 
documenting an increase in synapses in dyskinetic animals. These genes may be potential 
targets for drugs to ameliorate L-DOPA-induced dyskinesia or as an adjunct treatment to 
prevent their occurrence. 
 
3 
	
Highlights Ð 3-5 bullet points summarising findings 
¥ RNA-seq used to profile gene expression changes between dyskinetic and non-
dyskinetic animals in L-DOPA-induced dyskinesia. 
¥ Dyskinetic animals have elevated expression of cytoskeletal elements, a potential 
mechanism for increased dendritic spines. 
¥ Cytoskeletal elements present a potential target for treatments to prevent or ameliorate 
L-DOPA-induced dyskinesia. 
 
Keywords Ð max 6 words or phrases 
RNA-seq, dyskinesia, 6-OHDA, L-DOPA, striatum, ParkinsonÕs disease. 
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1. Introduction  
ParkinsonÕs disease (PD) is the second most prevalent neurodegenerative disorder worldwide, 
estimated to affect 0.3% of the general population (Tanner and Aston, 2000). At the onset of 
motor symptoms (resting tremor, bradykinesia, rigidity, and postural instability) more than 
half of dopaminergic neurons have degenerated (Barbeau, 1960; Ehringer and Hornykiewicz, 
1960; Barbeau et al., 1961), resulting in a loss of 80% of the dopamine in downstream nuclei, 
including the striatum (Ehringer and Hornykiewicz, 1960). The primary drug treatment for 
ParkinsonÕs disease is replacement of endogenous dopamine with the precursor substance L-
DOPA (Kaplan and Tarsy, 2013), in order to restore striatal function (Nicola et al., 2000).  
 
L-DOPA treatment provides relief from the motor symptoms of ParkinsonÕs disease, however 
the half-life of L-DOPA is only 50 - 90 minutes (Fabbrini et al., 1988; Olanow et al., 2000; 
Kang et al., 2010), and storage of dopamine is altered in the Parkinsonian brain (Lotharius 
and Brundin, 2002). Thus PD patients require multiple doses of L-DOPA during the course of 
a day, which can lead to a number of side effects, including dyskinesia. L-DOPA-induced 
dyskinesia are additional, unwanted, and often abnormal movements that develop with 
ongoing L-DOPA treatment. Dyskinesia may affect all areas of the body, including the head 
and neck, limbs, and torso; interfering with the process of everyday tasks (Barbeau, 1969).  
 
Three major risk factors for development of L-DOPA-induced dyskinesia are: age at 
diagnosis of ParkinsonÕs disease, initial L-DOPA dose, and length of treatment. A diagnosis 
before the age of 50 is associated with a 1.5 fold increase in dyskinesia incidence, and an 
initial dose of L-DOPA of more than 600 mg increases the risk of developing dyskinesia 1.4 
fold (Grandas et al., 1999). Treatment with L-DOPA for a period of five years or more will 
almost always result in development of dyskinesia (Ahlskog and Muenter, 2001). Given the 
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prevalence and impact of L-DOPA-induced dyskinesia, it is critical to understand their 
etiology, in order to develop effective treatments to minimise dyskinesia and, in the long term, 
prevent them from developing altogether.  
 
In animal models of ParkinsonÕs disease, the development of dyskinesia is associated with an 
alteration in synaptic plasticity mechanisms in neurons in the striatum (Picconi	et	al.,	2003). 
In a healthy animal, excitatory cortical axons that synapse onto striatal neurons can induce 
both an increase in synaptic transmission (long term potentiation, LTP) and a decrease in 
synaptic transmission (long term depression, LTD) following particular patterns of afferent 
stimulation (Reynolds and Wickens, 2000; Reynolds et al., 2001). Parkinsonian animals are 
unable to induce corticostriatal LTP without dopamine present (Picconi	 et	 al.,	 2003), 
however, only non-dyskinetic animals are able to induce de-potentiation, suggesting that the 
presence of dyskinesia is associated with an inability to reverse previously reinforced motor 
patterns. We hypothesise that changes in signalling will be accompanied with changes in gene 
expression.  
 
The development of transcriptomic technologies (e.g., microarrays, RNA-seq) has facilitated 
large-scale investigation of the pattern of gene expression changes in the brain following 
treatments. Indeed several studies have investigated the changes associated with dyskinesia 
using this approach (Konradi et al., 2004; El Atifi-Borel et al., 2009; Heiman et al., 2014). 
These studies, however, only investigated gene expression in response to a large-dose 
challenge (El Atifi-Borel et al., 2009), or after brain levels of L-DOPA had markedly reduced 
(e.g. 18 hours after the last dose; Konradi et al., 2004).  
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Here, for the first time, we use RNA-seq technology to examine global changes in striatal 
gene expression between dyskinetic and non-dyskinetic animals, at a time point consistent 
with peak-dose dyskinesia (Kang et al., 2010). We use a model of L-DOPA-induced 
dyskinesia where all treated animals received the same L-DOPA dose but only half displayed 
dyskinesia at three weeks of treatment (Picconi et al., 2011). This provides a control group 
(non-dyskinetic) that has been subjected to exactly the same chronic treatment regimen as the 
experimental group (dyskinetic). Using these animals we examined the gene expression 
changes at the peak of L-DOPA levels in the blood, 60 minutes after the last L-DOPA 
injection (Kang et al., 2010), with the aim of identifying genes associated with peak-dose 
dyskinesia that could act as potential drug targets in the future.  
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2. Experimental procedures  
2.1 Animals 
18 male Wistar rats were obtained and housed in the Hercus Taieri Research Unit at the 
University of Otago. All rats were used in each aspect of the study. Rats were housed on a 12-
hour reverse light-dark cycle with food and water ad libitum. All procedures were approved 
by the University of Otago Animal Ethics Committee.  
 
2.2 Lesioning and behavioural testing 
At 7-weeks of age rats received a unilateral lesion of the medial forebrain bundle using 6-
hydroxydopamine (6-OHDA). Rats were anesthetised with ketamine (7.5 mg/kg s.c., Phoenix 
Pharm) and domitor (0.5 mg/kg, s.c., Orion Pharma) with atropine (0.05 mg/kg, s.c., Phoenix 
Pharm). Local anesthetic (bupivacaine 5%, Astra Zeneca) was injected at the incision site and 
the rat placed in the stereotaxic frame. The neurotoxin 6-OHDA HBr (Sigma-Aldrich) was 
administered to the left medial forebrain bundle via a cannula placed at +4.4 mm AP, +1.2 
mm ML, and -8.3 mm DV to bregma (relative to the skull surface). 6-OHDA was 
administered at a concentration of 6 µg dissolved in 3 µl of 0.9% saline solution containing 
0.008% L-ascorbic acid (Sigma-Aldrich) and infused at a rate of 0.3 µl/min (Parr-Brownlie et 
al., 2007). Noradrenergic neurons were preserved by administration of desmethylimipramine 
(desipramine hydrochloride, Sigma-Aldrich, 4.5mg/kg administered 30 minutes prior to 
surgery). Rats received pain relief (carpreive 5 mg/kg s.c., Norbrook) and anesthetic reversal 
(antisedan 2.5 mg/kg s.c. Orion Pharma,) before being placed in a warm fresh cage for post-
operative recovery. Soft chow was provided ad libitum post-operatively to maintain weight. 
Five days after lesion surgery, lesion extent was examined using the adjusting step test 
(Olsson et al., 1995) and the forelimb use asymmetry test (Schallert et al., 2000); significance 
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was assessed using Excel 2011 with a paired StudentÕs t-test for the adjusting step test and a 
one-way ANOVA for the forelimb asymmetry test 
 
2.3 L-DOPA dosing and Abnormal Involuntary Movement scoring 
Two weeks after lesion surgery, successfully lesioned rats (n = 18) were divided randomly 
into two groups, L-DOPA treated and parkinsonian untreated. The L-DOPA treated group 
(2/3 of the lesioned rats) received 3-4 mg/kg of L-DOPA (dissolved in saline 1 ml/kg with 7.5 
mg/kg of benserazide HCl to prevent peripheral degradation) s.c. twice daily for three weeks. 
The remaining 1/3 of lesioned rats formed the parkinsonian untreated group and received 
equivalent volumes of saline plus benserazide (vehicle) s.c. on the same treatment schedule. 
At the end of each week dyskinesia was scored 60 minutes after an L-dopa dose using the 
well-established Abnormal Involuntary Movements (AIM) scoring for rodents (Winkler et al., 
2002). Rats were evaluated for axial dystonia, forelimb dyskinesia, and orolingual dyskinesia; 
and combined to give an aggregate AIM score each week. Rats were defined as non-
dyskinetic when the aggregate AIM score was zero for all three weeks of treatment.  
 
2.4 Sacrifice, RNA extraction and sequencing 
At the completion of the L-DOPA treatment regime rats were sacrificed by	 decapitation	
using	 a guillotine 1-hour after the final L-DOPA or vehicle injection (6 dyskinetic, 6 non-
dyskinetic, and 6 untreated parkinsonian animals). Because a third of the rats were exhibiting 
peak-dose dyskinesia at the time of sacrifice, all animals were restrained in a decapaconeª at 
the time of sacrifice. Animals were previously familiarised with the decapacone daily for 
three days prior to sacrifice, to minimise restraint stress. The brain was rapidly removed, the 
lesioned striatum was dissected out and snap frozen on dry ice, and the remainder of the brain 
post-fixed in 4% paraformaldehyde for later confirmation of the lesion extent.  
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RNA extraction was performed using the Qiagen RNeasy
¨
 mini kit. RNA was quantified 
using the Qubit
¨
 RNA Broad Range assay kit and quality was assessed using the Agilent 
2100 Bioanalyzer and the Agilent RNA 6000 Nano Kit (Agilent Technologies). To minimise 
differences attributable to variation between individuals RNA was pooled for RNA-seq 
analysis. RNA from sets of three animals was combined based on RNA concentration, 
resulting in two pools of 2 µg of RNA per group (dyskinetic, non-dyskinetic, and untreated 
parkinsonian). The RNA that was not used for the RNA-seq pools was stored at -80¡C and 
used for subsequent RT-qPCR verification of RNA-seq results.  
 
RNA-seq was performed using the Illumina HiSeq 2000 platform (service provided by BGI, 
Shenzhen, China). Each sample (pool) produced 12 million single end reads of 50 base pairs.  
Tarazona et al. (2011) demonstrated that this depth of sequencing was able to detect 
transcripts from approximately 18,000 genes in human brain samples, and thus provides good 
coverage of the transcriptome. It is possible that low abundance RNAs as well as smaller 
RNAs may be missed by this approach, although RNA-seq has a many-fold greater dynamic 
range than microarrays, so its ability to quickly and accurately assess cellular transcription is 
in general excellent (Wilhem et al. 2009). Relative to microarrays, RNA-seq has the 
advantage of not pre-selecting for known genes or genes of interest. That is, as more genomic 
elements are discovered/annotated, the alignment process can be rerun using the existing 
sequence data and updated genome annotation Ð there is no requirement to generate new RNA 
samples, as would be the case with microarrays.  
 
Bioinformatic analysis was performed using CLC Genomics Workbench version 6 (CLC bio) 
(Cameron et al., 2013). Adaptor sequences, contamination and low quality reads were 
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removed by the sequence service provider. Reads were mapped to the annotated rat genome 
(RGSC v 3.4.65) using the RNA-seq tool with an average mapping rate of 87%. In total the 
tool mapped reads against 29,516 annotated rat genes and resulted in positive reads (at least 1 
read) for 18,919 genes. Non-specific matches (more than two mismatches per read) were 
discarded, as were multiply mapped reads. Expression values were calculated based on reads 
that uniquely mapped to a gene (unique gene counts). Samples underwent quantile 
normalisation before being combined within groups. The correlation between the two pools 
which combined made up a treatment group was R
2
 = 0.99 for all three treatment groups 
indicating a high degree of similarity between the two pools. Differences in gene expression 
between treatment groups (dyskinetic, non-dyskinetic, and untreated parkinsonian) were 
assessed using the Baggerly test (Baggerly et al., 2003) with the Benjamini and Hochberg 
correction (Benjamini and Hochberg, 1995) used to control for multiple testing.  The 
Baggerly test is similar to a two sample t-test but the test statistic is weighted by the number 
of reads in each sample (Baggerly et al., 2003). An adjusted p-value of 0.05 was used as the 
threshold for significance (Cameron et al., 2013).  A subset of genes were selected for further 
examination, based on their role as transcription factors and genes known to be activated soon 
after dopamine receptor stimulation (Cole et al., 1992; Moratalla et al., 1992; Berke et al., 
1998). These genes: Arc, Egr1, Fos, Junb, and Nr4a1, were examined using TaqMan gene 
expression probe sets (Life Technologies) to confirm gene expression patterns observed in the 
RNA-seq dataset. This was conducted using pooled RNA that had been conserved prior to 
construction of the RNA-seq libraries. Gene expression quantification was conducted using a 
Roche LightCycler 480 and expression normalised to two standards Tbp and Slc35f2 based on 
a pilot study of reference genes in this tissue (data not shown). Differences between groups 
were analysed using a one-way ANOVA with a Turkey post-hoc test, with a p-value threshold 
of <0.05.  
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Gene set cluster analysis was performed using the online Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.7 (Huang da et al., 2009) with the full 
expressed gene set as a background and a FisherÕs exact test limit of 0.1. This analysis 
identified sets of genes with similar functions that are overrepresented in the sample. The top 
ten gene set categories are shown in the results section.  
 
2.5 Confirmation of lesion extent using tyrosine hydroxylase immunohistochemistry 
Brain slices were cut on a vibratome in 50 µm sections, and every second section containing 
the substantia nigra was stained for tyrosine hydroxylase immunoreactivity.  The primary 
antibody was Millipore rabbit anti-tyrosine hydroxylase (AB152) diluted 1:1600 and applied 
for 24 hours at 4 ¡C. The Vectastain Elite ABC Rabbit IgG kit (Vector Laboratories) was then 
used. Immunoreactivity was visualised with 3,3'-diaminobenzidine reacted for 5 minutes. 
Slides were visualised using a Zeiss Axioskop light microscope at 5x and 10x magnifications. 
Images were photographed at 10x with an Olympus DP71 camera and processed using the 
Olympus micro DP controller, before being saved as JPEG files. JPEG files were processed 
for cell counts using MBF-Image J software as previously described (Clements et al., 2012). 
Three sections were examined per brain; with the substantia nigra pars compacta outlined in 
Image-J prior to cell count procedures. Cell counts are presented as percentage of the non-
lesioned hemisphere and differences between hemispheres were calculated using a paired 
StudentÕs t-test (Excel 2011).  
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3. Results  
3.1 Analysis of lesion extent 
The extent of the dopaminergic lesion was estimated pre-mortem and post-mortem (Figure 1). 
Pre-mortem estimates used the adjusting step test and forelimb use asymmetry test (Olsson et 
al., 1995; Schallert et al., 2000; Tseng et al., 2005; Parr-Brownlie et al., 2007). Successfully 
lesioned animals used the affected right paw for less than 5% of movements in both the step 
test (Figure 1 A; p < 0.001, F = 259) and the asymmetry test (Figure 1B; p < 0.001, F = 899). 
Following all experimental procedures, lesion extent was confirmed post-mortem by 
immunohistochemical analysis of the substantia nigra pars compacta (SNc; Figure 1 G). In 
the lesioned hemisphere less than 5% of dopaminergic neurons remained in the SNc 
compared with the intact hemisphere; p<0.05 (Figure 1 H; p  < 0.001, F = 177). 
 
3.2 Rating of L-DOPA-induced dyskinesia 
L-DOPA-induced dyskinesia status was evaluated one hour after L-DOPA injection using the 
rat AIM rating scale (Winkler et al., 2002). All dyskinetic animals showed a positive score in 
each of the three categories examined (axial dystonia - Figure 1 C, forelimb dyskinesia Ð 
Figure 1 D, and orolingual dyskinesia Ð Figure 1 E), with an average total score of 7.1 ± 2.5 
(mean ± S.D.; Figure 1 F). Non-dyskinetic animals were defined as animals that scored zero 
in all categories examined (Figure 1 F), with an overall score of zero; similarly, untreated 
parkinsonian animals showed no signs of abnormal involuntary movements.  The difference 
between groups was statistically significant (p < 0.001, F = 38). It was noted during AIMs 
analysis that non-dyskinetic animals displayed an improvement in overall locomotor ability, 
however this was not specifically tested and thus not quantified.  
 
3.3 RNA-seq profiles 
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Transcriptomic analysis was performed on total RNA samples isolated from the lesioned 
striatum of dyskinetic, non-dyskinetic, and untreated parkinsonian animals 1-hour following 
the final L-DOPA or vehicle injection. This allowed examination of the striatial gene 
expression profiles of dyskinetic, non-dyskinetic, and untreated parkinsonian animals at the 
peak L-DOPA effectiveness. Significant differences in gene expression were observed 
between all three groups (Figure 2); 267 genes were differentially expressed in total (Figure 2 
A; Table 1), with 129 more highly expressed and 14 less highly expressed in L-DOPA treated 
dyskinetic animals and non-dyskinetic animals (Figure 2 B and 2 C; total genes enclosed 
within complete topmost circles). In L-DOPA treated animals (both dyskinetic and non-
dyskinetic) 42 genes were more highly expressed and 95 less highly expressed when 
compared with untreated parkinsonian controls (Figure 2 B and 2 C; total genes enclosed 
within both of the lowermost circles).  A subset of genes was selected for further examination, 
based on their role as transcription factors and immediate early genes, known to be activated 
in response to dopamine receptor stimulation (Cole et al., 1992; Moratalla et al., 1992; Berke 
et al., 1998). Expression was examined in RNA from the individual rats in the RNA-seq 
experiment using RT-qPCR to verify patterns observed in the RNA-seq dataset and the results 
compared with the RNA-seq counts (Figure 3). There was a positive correlation (R
2
 = 0.834) 
between the RNA-seq and qPCR data. The data points that did not conform may be due to the 
effect of pooling RNA in RNA-seq samples compared with individual animal RNA examined 
with RT-qPCR or the sensitivity associated with qPCR.  
 
3.4 Gene ontology analysis 
Gene ontology analysis revealed changes between all groups (Figure 4). One interesting 
change was a decrease in expression of genes involved in DNA-binding, transcription, and 
regulation of transcription in L-DOPA-treated dyskinetic and non-dyskinetic animals 
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compared with their untreated parkinsonian controls (Figure 4 B and C). In particular 
immediate early genes and transcription factors were decreased in dyskinetic animals 
compared with untreated parkinsonian controls (Atf3 -6.91 fold, FDR 0.04; Fos -7.33 fold, 
FDR 1.52E-158; Fosb -3.98 fold, FDR 9.03E-29; Egr1 -2.93 fold, FDR 2.72E-94; Egr2 -6.65 
fold, FDR 1.63E-06; Egr3 -1.59 fold, FDR 5.8E-06; Egr4 -2.31 fold, FDR 4.08E-43; Junb -
3.55 fold, FDR 6.61E-26; Nr4a1 -2.62 fold, FDR 2.65E-41; Nr4a3 -2.96 fold, 1.97E-60).  
 
Gene enrichment analysis revealed dyskinetic animals exhibit a distinct increase in expression 
of genes involved in cytoskeletal organisation, cytoplasmic vesicles, endocytosis, and 
phosphoproteins compared with the non-dyskinetic animals (Figure 4 A). In particular dynein 
complex genes (Dnaaf3 2.31 fold, FDR 0.01; Dnah1 3.01 fold, FDR 0.01; Dnah2 2.12 fold, 
FDR 5.11E-09; Dnah11 2.3 fold, FDR 7.23E-09; Dnah10 1.94 fold, FDR 0.04), integrin 
(Itgb4 2.74 fold, FDR 0.04), actin (Acta1 1.62 fold, FDR 0.03), and activity related 
cytoskeletal genes (Arc 1.51 fold, FDR 9.8E-03) were increased in dyskinetic animals 
compared with non-dyskinetics. This indicates a potential change in cytoskeletal structure and 
signalling in dyskinetic animals.  
 
Phosphoproteins that were increased in dyskinetic animals include aurora kinase B (Aurkb 
7.81 fold, FDR 2.96E-08), calcyon neuron-specific vesicular protein (Caly 1.2 fold, FDR 
0.02), protein phosphatase 1 regulatory subunit 15a (Ppp1r15a 1.34 fold, FDR 3.9E-04), and 
regulator of g-protein signalling 14 (Rgs14 1.56 fold, FDR 1.28E-03).   
 
4.  Discussion  
L-DOPA remains the gold standard treatment for alleviating symptoms in PD patients, 
however the majority of patients will develop dyskinesia with prolonged L-DOPA treatment. 
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The experiments presented here examined the gene expression profile associated with L-
DOPA-induced dyskinesia at the peak of L-DOPA dose with the aim of finding patterns of 
gene expression changes related to the most common form of dyskinesia in humans, so-called 
peak-dose dyskinesia. This is a unique timepoint; previous studies have examined gene 
expression changes that are not attributable to the peak of L-DOPA concentration. This has 
left us with a dearth of understanding about changes occurring at the peak of L-DOPA 
concentration in the brain that might underlie the chronic behavioural characteristics related to 
dyskinesia. According to Jenner Òit is still unclear how striatal output contributes to 
dyskinesia É this makes improving our understanding difficult: in both MPTP-treated 
primates and 6-OHDA-lesioned rats, the task of distinguishing the causes and consequences 
of dyskinesia is a major challengeÓ (Jenner, 2008).  Such understanding is required for the 
development of therapies that might ameliorate the debilitating effects of dyskinesia or 
prevent their development.  
 
We found 267 genes to be significantly differentially expressed between dyskinetic, non-
dyskinetic, and/or untreated parkinsonian controls at the peak of L-DOPA dose. Of those, 
almost half (143) of the differences were observed between the dyskinetic and non-dyskinetic 
groups. The majority of differentially expressed genes were more highly expressed in the 
dyskinetic group compared to the non-dyskinetic and untreated parkinsonian groups. qPCR 
validation of the RNA-seq gene expression patterns confirmed the data with a strong positive 
association identified (R
2
 = 0.834) and the non-conforming genes were typically those with 
small fold changes. 
 
Gene ontology analysis showed enrichment in cytoskeletal-associated genes between 
dyskinetic and non-dyskinetic rats. Recent microscopy studies examining differences in the 
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spines of striatal neurons found an increase in the number of cortico-striatal synapses in L-
DOPA-treated rats compared with untreated parkinsonian controls (Zhang et al., 2013; 
Fieblinger et al., 2014). Changes in synapse number or size require changes to the underlying 
architecture of the neuron, the cytoskeletal frame.  Interestingly, we observed changes in the 
genes underlying cytoskeletal architecture; namely dynein complex, ephrin b, cadherin, and 
integrin genes were more highly expressed in dyskinetic rats compared to both untreated 
parkinsonian controls and non-dyskinetic animals. Cadherins and catenins, along with Arc, 
are known to interact with and alter the actin cytoskeleton structure (Tanaka et al., 2000; 
Drees et al., 2005); Figure 5). We propose that this increase in transcription may indicate a 
mechanism for the previously observed increase in the number of synapses in dyskinetic 
animals (Zhang et al., 2013; Fieblinger et al., 2014). However, our changes were observed on 
a timescale consistent with peak-dose dyskinesia, whereas Zhang et al (2013) made these 
observations 72 hours after the last dose. There is evidence that spine morphology changes 
can occur within a period of <30 minutes (Maletic-Savatic et al., 1999; Nikonenko et al., 
2002). Hence, it is possible that the changes in gene expression we observed may underlie 
changes in the cytoskeleton in response to acute L-DOPA dosing, although a systematic 
comparison with changes in these genes, their protein products, and microscopy to highlight 
subcellular changes in cytoskeletal networks on a chronic timescale would be needed to draw 
this conclusion. If this association occurs at the protein level then cytoskeletal elements 
represent a potential drug target area for treatment of L-DOPA-induced dyskinesia. 
Pharmacological agents that modify cytoskeletal elements could be administered in 
conjunction with L-DOPA/benserazide in order to decrease the expression of selected 
cytoskeletal genes and prevent the increase in synaptic number. However, given the 
ubiquitous nature of cytoskeletal architecture across the brain and indeed the body, any 
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potential drugs will need to be thoroughly tested for side-effects, or drugs targeted 
specifically to the striatum, when such approaches become readily available.  
 
Parkinsonian animals show impairment in the ability to induce synaptic potentiation in 
response to electrical stimulation, which is overcome with dopamine treatment. However, 
only non-dyskinetic animals are able to show subsequent depotentiation (Picconi et al., 2003). 
Our results showed enrichment for 37 phosphoproteins in dyskinetic animals compared with 
non-dyskinetic animals. The increase in expression of genes encoding phosphoproteins 
observed in this study is  consistent with previous findings that dyskinetic animals have 
increased phosphorylated DARPP32 (Picconi et al., 2003), ERK (Pavon et al., 2006; Santini 
et al., 2007; Westin et al., 2007), and MEK (Santini et al., 2007) resulting in increased 
potentiation at synapses and impaired depotentiation. Drugs that reverse protein 
phosphorylation (phosphatases) represent a potential treatment avenue that could be used to 
reduce the phosphorylation of phosphoproteins we have identified as being expressed and 
potentially rescue depotentiation at synapses in dyskinetic animals. Previous studies have 
shown that blocking an inhibitor of protein phosphatase 1 in dyskinetic animals rescues the 
ability to depotentiate (Picconi et al., 2003); our paper suggests further targets for protein 
phosphatase treatment. However, these drugs will need to be specifically targeted to the brain 
region and specific phosphoprotein to minimise off-target effects given that phosphorylation 
is a key part of normal cell-signalling.  
 
In contrast to the signalling changes observed between dyskinetic and non-dyskinetic animals, 
differences in mRNA expression between L-DOPA treated and untreated parkinsonian 
controls were primarily genes associated with DNA binding, transcription, and regulation of 
transcription. Untreated parkinsonian controls did not receive L-DOPA at any point in the 
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study, thus this is a result of one group of animals receiving an intervention (L-DOPA) and 
the controls receiving no effect from the vehicle injection. In addition, the changes identified 
between the dyskinetic and non-dyskinetic animals were different to those of untreated 
parkinsonian controls, and thus not a reflection of a failed L-DOPA injection (non-dyskinetic).  
 
This is the first study to use RNA-seq analysis of the transcriptome to compare the overall 
profile of gene expression in the striatum of dyskinetic, non-dyskinetic, and untreated 
parkinsonian animals at the height of L-DOPA-induced dyskinesia expression. Our results 
imply that genes and proteins involved in cytoskeletal processes may be a potential target for 
drugs to treat L-DOPA-induced dyskinesia. However, our results have been obtained using an 
analysis of tissue RNAs, which will show changes over all cell types. Recent studies have 
shown that a cell-type specific analysis can better differentiate functional changes in protein 
phosphorylation and gene expression (Heiman et al., 2014). Given the influence that small 
populations of neurons such as cholinergic interneurons have with respect to dyskinesia (Ding 
et al., 2011; Won et al., 2014), extensive further study is required, focussing on the 
contribution of single populations of cells to the overall gene expression pattern.  
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Figures Legends 
Figure 1.  Pre-mortem assessment of lesion extent and dyskinesia score, and post-mortem 
confirmation of the extent of lesion. Pre-mortem behavioural tests indicate 
successful lesion; the affected right paw makes < 5% of the steps the 
unaffected left paw makes in the adjusting step test A and the cylinder-based 
forelimb use asymmetry test B. Animals were assessed for dyskinetic 
behaviour after three weeks of L-DOPA dosing. Three categories were 
assessed: axial dystonia C, forelimb dystonia D, and orolingual dystonia E, to 
give a final dyskinesia extent score out of 12 F. Animals who received L-
DOPA but scored a zero total dyskinesia score at week three were classified as 
non-dyskinetic. Animals who did not receive L-DOPA did not show any signs 
of dyskinesia during assessment. A dyskinetic animal was one who scored at 
least 1 in the total dyskinesia score at week three. At the conclusion of the 
experiment post-mortem tyrosine hydroxylase immunohistochemistry 
confirmed >95% loss of dopamine neurons (Example brain slice G, 
quantification H). Total dyskinesia scores for untreated parkinsonian and non-
dyskinetic animals depict the absence of any dyskinesia signs in any animals 
but the dyskinetic group F. All data are shown as mean ± standard deviation. * 
indicates a p-value of < 0.05 denoting significance, which was assessed using a 
StudentÕs t-test for A and H and a one-way ANOVA for B, C, D, E and F.	
	
Figure 2. RNA-seq analysis of differential gene expression between groups 1-hour after 
L-DOPA or vehicle treatment (Untreated parkinsonian control). Overall 
expression changes are shown (A), those where expression was highest in the 
first group of the comparison (B) and those where expression was lowest in the 
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first group of the comparison (C). Overall there were 267 differentially 
expressed genes (found by the summation of the numbers in A). Differences 
between groups were assessed using a Baggerly test (Baggerly et al., 2003) 
and the threshold for a significant difference was a Benjamini and Hochberg 
adjusted p-value of <0.05. 
 
Figure 3.  Concordance of changes in gene expression between RNA-seq and qPCR 
experiments. Comparison was made between the RNA-seq counts and qPCR 
results for five genes of interest. For qPCR all genes were normalised to Tbp 
and Slc35f2 and all results were normalised to the untreated parkinsonian 
group. There was a positive correlation between the RNA-seq counts and 
qPCR results (R
2
 value 0.83). 
 
Figure 4.  DAVID Gene ontology analysis conducted to identify gene set enrichment. 
Genes ontology terms enriched in the comparison between dyskinetic and non-
dyskinetic A, dyskinetic and untreated parkinsonian B, and non-dyskinetic and 
untreated parkinsonian C. Gene ontology terms are listed in order of 
significance, as assessed with FisherÕs exact test (bottom axis, black line) and 
show the number of genes identified as significantly changed (top axis, green 
bars) that fit into a classification group.  
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Figure 5. Schematic of postsynaptic protein interactions thought to be altered in 
dyskinetic L-DOPA-treated animals. Activation of NMDA and dopamine D1 
receptors induces changes in MAPK signalling, phosphorylating the 
transcription factor ERK. The dynein protein complex (purple) then transports 
transcription factors (e.g. ERK) down microtubules to the dendritic shaft and 
cell soma to induce changes in gene transcription. Kinesin (brown) transports 
proteins such as ARC to the dendritic spine. ARC interacts with: (i) actin and 
actin binding proteins to induce activity-related changes in spine shape and 
structure (Tanaka et al., 2000; Drees et al., 2005); (ii) AMPA receptors to 
induce internalisation of these receptors, resulting in increased glutamate 
activation of NMDA receptors; and (iii) integrin to stabilise the spine structure 
in its altered state. Figure based on gene expression changes observed in this 
study, which are indicated with green arrows, as well as from Tai et al. (2008) 
and Dalva et al. (2007). 
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!Table 1.  Summary table of all gene expression changes identified. D Ð dyskinetic, N 
Ð non-dyskinetic, and P Ð untreated parkinsonian control.  
Feature ID D v N D v P N v P 
 Fold change FDR p-value  Fold change FDR p-value  Fold change FDR p-value  
Acta1 1.62 0.03 -1.09 1.00 1.48 0.15 
Ankrd34c -2.53 0.01 1.80 0.63 -1.40 0.93 
Apold1 1.80 0.02 -4.10 9.58E-09 -2.27 5.84E-07 
Arc 1.51 9.84E-03 -4.02 3.12E-18 -2.66 1.08E-18 
Arnt2 1.21 0.02 -1.05 0.98 1.15 0.93 
Arpp21 1.29 5.11E-09 -1.10 0.51 1.17 0.34 
Atp6ap1l 1.45 7.23E-09 -1.05 0.99 1.38 7.09E-03 
Atp6v1a 1.15 2.56E-04 -1.10 0.09 1.05 0.93 
Aurkb 7.81 2.96E-08 -1.28 1.00 6.10 0.93 
Blcap 1.19 0.01 -1.09 0.85 1.10 0.79 
Btg1 1.30 8.95E-03 -1.31 0.32 -1.01 1.00 
Cadm3 1.20 2.93E-08 -1.05 1.00 1.14 0.93 
Calm1 1.12 1.46E-54 -1.00 1.00 1.12 0.00 
Caly 1.20 0.02 1.03 1.00 1.23 3.63E-05 
Cbr3 1.98 2.30E-03 -1.22 0.94 1.62 0.87 
Ccdc108 9.23 4.84E-03 -1.07 1.00 8.63 0.93 
Ccdc135 3.76 6.17E-04 -1.17 1.00 3.22 0.83 
Ccdc146 2.38 5.39E-03 -1.00 1.00 2.38 0.93 
Ccdc151 3.99 2.52E-03 1.26 0.94 5.01 2.77E-05 
Ccdc153 5.01 4.18E-09 1.13 1.00 5.66 0.93 
Ccdc162 4.22 5.66E-05 1.15 1.00 4.87 0.93 
Ccdc176 1.48 0.02 -1.10 0.95 1.35 0.59 
Ccdc19 3.48 0.03 -1.17 1.00 2.97 0.93 
Ccdc37 1.86 0.02 -1.14 1.00 1.63 0.93 
Ccdc39 1.24 6.45E-03 -1.04 1.00 1.20 0.93 
Ccdc50 -1.32 0.02 1.11 0.94 -1.19 0.59 
Ccdc78 3.40 0.02 1.03 1.00 3.49 0.67 
Cd24 1.71 1.14E-09 -1.11 0.94 1.55 8.34E-04 
Cdca7 5.25 6.22E-09 -1.50 0.95 3.49 0.93 
Cdh2 1.18 8.43E-03 -1.14 0.15 1.04 0.97 
Cdh29 7.79 6.34E-07 1.02 1.00 7.97 0.93 
Celsr1 1.74 2.26E-04 -1.27 0.61 1.37 0.39 
Cntnap3 1.83 2.90E-04 -1.18 0.94 1.56 0.59 
Cpne6 1.52 5.30E-04 -1.14 0.94 1.34 0.82 
Cyp7b1 1.46 2.09E-04 -1.28 0.01 1.14 0.93 
Cyr61 1.90 0.02 -14.66 3.84E-20 -7.70 1.78E-04 
Dbi -2.06 3.35E-03 1.49 0.69 -1.39 0.69 
Dlx1 2.54 0.02 -1.51 0.94 1.68 0.89 
Dnaaf3 2.31 0.01 1.32 0.94 3.05 9.67E-06 
Dnah1 3.01 0.01 -1.00 1.00 3.00 0.93 
Dnah10 1.94 0.04 -1.14 1.00 1.70 0.95 
Dnah11 2.30 7.23E-09 -1.07 1.00 2.15 0.76 
Dnah2 2.12 5.11E-09 -1.03 1.00 2.05 0.93 
Dnah6 6.48 1.01E-03 -1.17 1.00 5.52 0.91 
Dos 1.14 2.52E-03 -1.13 0.02 1.02 1.00 
Drc1 2.15 3.14E-03 -1.54 0.94 1.40 0.95 
Dusp1 1.45 0.01 -4.60 6.38E-43 -3.18 5.32E-11 
Dynlrb2 3.28 1.01E-04 1.13 1.00 3.69 0.40 
Efnb1 1.60 0.04 -1.18 0.94 1.35 0.69 
Egr1 1.32 9.36E-05 -2.39 2.72E-94 -1.81 8.87E-12 
Egr4 1.27 5.05E-06 -2.31 4.08E-40 -1.82 2.35E-16 
Enkur 1.92 6.03E-07 -1.19 1.00 1.61 0.93 
Erf 1.23 0.01 -1.28 5.78E-03 -1.05 0.99 
Fam214a 1.16 7.43E-03 -1.16 0.45 -1.00 1.00 
Fam81b 1.26 2.18E-03 -1.06 0.94 1.19 0.13 
Fhad1 3.92 0.01 -1.31 1.00 2.99 0.93 
!Folr1 9.75 0.04 -1.41 1.00 6.92 0.93 
Fos 1.48 2.69E-13 -7.33 1.52E-158 -4.96 3.29E-86 
Fosb 1.47 2.72E-03 -3.98 9.03E-29 -2.72 1.31E-08 
Gad2 1.20 1.57E-04 -1.11 0.25 1.08 0.24 
Gpr149 1.65 5.71E-03 -1.05 0.99 1.57 0.04 
Grb10 1.21 6.43E-03 -1.10 0.76 1.10 0.80 
Gtf2ird1 1.18 0.03 1.00 1.00 1.18 0.43 
Hcn2 -1.23 6.34E-07 1.24 0.56 1.01 1.00 
Hnrph1 1.10 0.02 -1.13 6.65E-04 -1.03 0.93 
Hrh3 1.12 0.04 1.04 1.00 1.17 0.93 
Hydin 3.18 8.58E-05 1.38 1.00 4.37 0.93 
Iiig9 2.51 0.02 1.14 1.00 2.87 0.93 
Iqca1 1.67 0.04 1.05 1.00 1.75 0.93 
Iqcg 2.47 0.02 1.09 1.00 2.68 0.13 
Itga1 -1.91 0.03 1.40 0.94 -1.37 0.83 
Itgb4 2.74 0.04 1.23 1.00 3.37 0.93 
Junb 1.47 0.02 -3.55 6.61E-26 -2.41 3.84E-09 
Kcnk16 7.54 1.68E-03 -1.23 1.00 6.11 0.93 
Klf5 1.50 7.69E-03 -1.71 1.62E-03 -1.14 0.93 
Kmt2a 1.09 0.02 1.01 1.00 1.11 0.93 
Kpna3 1.16 0.04 -1.16 0.37 1.00 1.00 
Krt8 9.83 0.04 1.07 1.00 10.50 0.93 
Ldb2 1.34 1.89E-03 -1.02 1.00 1.31 8.25E-06 
LOC679641 4.08 0.01 1.06 1.00 4.31 0.93 
Lpl 1.37 7.57E-03 -1.06 1.00 1.29 0.93 
Lrrc34 2.06 0.04 -1.06 1.00 1.94 0.93 
Lrriq1 2.86 5.05E-06 -1.38 0.94 2.07 0.87 
Map2 1.06 0.02 -1.04 1.00 1.02 1.00 
Mapk15 2.72 2.34E-05 -1.11 1.00 2.46 0.63 
Mki67 2.34 8.95E-03 -1.39 0.95 1.69 0.93 
Mllt11 1.15 0.01 -1.15 0.40 -1.00 1.00 
Mns1 1.53 0.04 1.11 1.00 1.69 0.76 
Mtnd4l 1.07 2.84E-52 -1.07 1.42E-52 -1.00 1.00 
Mylk -1.57 2.34E-05 1.09 0.96 -1.44 2.17E-03 
Nptx1 1.99 0.01 -1.23 0.99 1.62 0.93 
Nr4a1 1.45 6.22E-17 -2.62 2.65E-41 -1.80 1.08E-10 
Nr4a3 1.39 8.03E-11 -2.96 1.97E-60 -2.12 4.33E-22 
Nrsn2 1.19 0.04 -1.02 1.00 1.17 0.16 
Nup210l 1.63 0.04 -1.28 0.94 1.27 0.93 
Obscn 1.93 0.01 -1.61 0.25 1.20 0.99 
P2rx6 2.07 2.59E-03 -1.01 1.00 2.05 0.93 
Pcmtd2 1.14 0.02 -1.10 0.33 1.04 0.93 
Pfkl 1.19 0.04 -1.07 0.99 1.12 0.93 
Pitpnm2 1.17 7.61E-03 1.02 1.00 1.19 0.30 
Ppap2b 1.13 0.03 -1.09 0.07 1.04 0.93 
Ppfia2 1.19 0.01 1.00 1.00 1.19 0.02 
Ppp1r15a 1.34 3.94E-04 -2.11 5.43E-20 -1.58 2.32E-05 
Ppp1r15b 1.21 0.03 -1.21 0.61 -1.00 1.00 
Prkg1 1.57 3.30E-03 -1.17 0.94 1.34 0.93 
Prr13 -1.68 9.48E-03 1.17 0.99 -1.44 0.73 
Psma8 16.00 0.04 -1.43 0.96 11.17 0.28 
Ptplad1 1.18 1.38E-03 -1.10 0.55 1.07 0.93 
Resp18 1.30 1.36E-03 -1.14 0.34 1.15 0.61 
Rgs14 1.56 1.28E-03 -1.30 0.46 1.20 0.76 
Rgs22 4.83 3.06E-03 -1.35 0.94 3.57 0.53 
Rsph4a 4.48 2.74E-03 -1.12 1.00 4.00 0.93 
Rtn4rl2 5.56 0.04 -1.85 0.94 3.00 0.80 
Scg5 1.11 0.03 -1.04 0.94 1.07 0.73 
Scml4 2.15 0.03 -1.12 1.00 1.92 0.93 
Sdcbp 1.24 0.01 -1.22 3.58E-04 1.02 1.00 
!Sept3 1.14 7.69E-03 -1.01 1.00 1.13 0.33 
Serinc2 2.54 7.38E-04 -1.04 1.00 2.44 0.93 
Slc2a3 1.31 9.48E-03 -1.18 0.46 1.11 0.93 
Sort1 -1.18 0.04 1.07 0.61 -1.10 0.77 
Srebf2 -1.15 0.04 1.04 0.94 -1.10 0.15 
Stpg1 3.65 2.34E-05 -1.03 1.00 3.55 0.93 
Stx6 -1.20 8.43E-03 1.18 0.04 -1.02 1.00 
Sv2c 1.24 1.54E-07 -1.02 1.00 1.22 0.69 
Synpo2 -1.40 0.02 1.11 0.94 -1.27 0.45 
T2 5.42 3.57E-03 -1.17 1.00 4.62 0.93 
Tagln -1.49 0.04 -1.12 0.98 -1.67 1.59E-05 
Tmem130 1.20 6.03E-04 -1.07 0.94 1.12 0.59 
Tmsb10 1.19 0.02 -1.03 1.00 1.15 0.93 
Tnnt1 1.52 0.01 1.03 1.00 1.57 4.53E-03 
Top2a 2.48 3.15E-03 -1.79 0.92 1.39 0.99 
Tpbg 1.52 3.27E-03 -1.01 1.00 1.51 0.23 
Tril -1.28 0.02 1.03 1.00 -1.24 0.11 
Ttc25 3.17 9.39E-06 -1.00 1.00 3.16 0.93 
Ttll10 6.40 0.04 1.52 1.00 9.75 0.93 
Vopp1 1.18 5.66E-03 -1.02 1.00 1.16 0.04 
Vwa5b1 2.47 3.43E-03 -1.03 1.00 2.39 0.93 
Wdr34 1.52 0.03 -1.11 0.94 1.37 0.39 
Wdr52 4.94 8.43E-03 1.02 1.00 5.02 0.92 
Wdr63 3.36 1.78E-03 1.57 0.94 5.27 0.10 
Wdr96 2.58 3.57E-03 -1.12 1.00 2.30 0.93 
Yipf1 -1.28 0.04 1.13 0.96 -1.13 0.93 
Ywhab 1.06 0.02 -1.03 0.69 1.03 0.93 
       
Akap8l 1.11 0.92 1.02 1.00 1.13 6.11E-05 
Aldoc -1.10 0.52 1.12 3.72E-03 1.02 1.00 
Arf4 1.11 0.31 -1.19 8.31E-03 -1.07 0.93 
Arhgap31 -1.31 0.05 -1.04 1.00 -1.36 0.02 
Arl4d 1.37 0.15 -2.19 2.91E-07 -1.59 2.17E-06 
Atf3 1.60 0.92 -6.91 0.04 -4.31 0.13 
Atp1a2 -1.08 0.92 -1.04 1.00 -1.12 9.18E-21 
B3gnt2 1.08 1.00 -1.21 9.81E-04 -1.12 1.00 
Bhlhe40 1.08 0.92 -1.38 7.58E-03 -1.28 0.04 
Blnk -1.19 0.92 -1.37 0.94 -1.63 4.96E-03 
Btg2 1.59 0.14 -5.75 1.21E-12 -3.61 1.59E-08 
Cacng1 -8.22 0.70 12.56 0.03 1.53 0.94 
Cadps2 1.55 0.92 -1.81 0.03 -1.17 1.00 
Cbln1 -1.33 1.00 -4.35 0.03 -5.77 0.93 
Ccnl1 1.04 1.00 -1.23 1.89E-03 -1.18 0.78 
Ccrn4l 1.19 0.24 -1.41 5.79E-05 -1.18 0.51 
Cdc42ep3 1.36 0.14 -1.67 4.68E-10 -1.23 0.93 
Celf4 1.22 0.05 -1.08 0.94 1.12 0.02 
Cited2 1.12 0.84 -1.28 0.01 -1.15 0.80 
Clgn 1.32 0.76 1.37 0.73 1.81 0.04 
Clmp -1.24 0.81 -1.38 0.69 -1.72 0.02 
Cnot8 1.13 0.92 -1.20 0.04 -1.06 1.00 
Col4a4 -1.67 0.38 -1.02 1.00 -1.71 0.02 
Coq10b 1.10 0.92 -1.69 2.24E-06 -1.53 1.35E-03 
Cpsf6 1.08 0.63 -1.14 0.04 -1.05 0.93 
Cspg4 -1.21 0.96 -1.18 1.00 -1.43 3.52E-05 
Ctgf 1.26 0.95 -1.53 0.04 -1.22 1.00 
Cygb -1.22 0.38 1.26 0.01 1.03 1.00 
Cyth4 -1.31 0.92 -1.15 1.00 -1.50 0.03 
Dclk1 1.12 0.92 -1.09 4.12E-03 1.03 1.00 
Ddit3 -1.05 0.99 -1.44 1.45E-03 -1.51 6.87E-05 
Dlx5 1.25 0.92 -1.29 0.03 -1.03 1.00 
!Dusp5 1.47 0.92 -3.18 0.08 -2.15 8.47E-03 
Dynlt3 -1.05 0.92 -1.14 0.42 -1.19 0.03 
Egr2 1.48 0.57 -6.65 1.63E-06 -4.49 8.48E-90 
Egr3 1.19 0.87 -1.59 5.80E-06 -1.34 0.19 
Eif4e 1.13 0.35 -1.19 0.04 -1.05 0.93 
Elp5 1.05 0.94 -1.26 6.44E-03 -1.20 0.13 
F8 -1.17 0.71 1.33 3.16E-03 1.14 0.87 
Fam115a 1.08 0.66 1.08 0.59 1.16 8.15E-03 
Fbxl3 -1.13 0.57 -1.14 0.63 -1.30 1.98E-03 
Fxyd7 1.55 0.08 1.07 1.00 1.65 0.02 
Gadd45g 1.70 0.42 -3.73 5.08E-24 -2.19 0.81 
Gldn -1.11 0.92 1.27 0.03 1.15 0.93 
Gltscr2 -1.11 0.79 1.24 0.01 1.12 0.69 
Golim4 -1.11 0.81 -1.16 0.49 -1.28 4.30E-03 
Gpr98 1.75 0.19 1.10 1.00 1.93 8.15E-03 
Herc2 -1.01 1.00 -1.17 0.05 -1.17 0.04 
Ip6k2 1.11 0.66 -1.17 0.03 -1.05 0.96 
Kif17 1.39 0.06 1.02 1.00 1.41 0.03 
Klf2 1.42 0.44 -1.96 0.03 -1.38 0.93 
Klf4 1.15 0.94 -1.99 0.03 -1.73 1.48E-03 
Lrmp 1.19 0.89 1.38 0.07 1.65 1.14E-04 
Lrrc23 1.58 0.59 1.30 0.94 2.05 0.04 
Lyn 1.05 1.00 -1.42 0.03 -1.35 0.15 
Mrpl15 1.15 0.57 1.12 0.91 1.29 0.01 
Nab2 1.18 0.92 -1.37 2.46E-04 -1.16 0.98 
Nckap1l -1.10 1.00 -1.34 0.94 -1.48 0.02 
Nefl -1.19 0.23 -1.03 1.00 -1.22 0.04 
Nfkbid 1.27 0.92 -3.03 2.11E-04 -2.39 0.04 
Nlrc3 2.42 0.12 -3.69 9.91E-03 -1.52 0.93 
Nop58 1.15 0.92 -1.22 0.02 -1.06 1.00 
Npas4 1.91 0.72 -5.58 0.01 -2.92 0.38 
Nsmce2 1.11 0.92 1.13 0.94 1.26 5.65E-03 
Ntrk2 1.04 0.92 -1.12 1.55E-09 -1.07 0.93 
Nupl1 -1.05 0.98 -1.17 0.71 -1.23 0.03 
Pcdh8 -1.41 0.92 1.50 5.03E-03 1.07 1.00 
Pde10a -1.09 1.00 1.12 5.81E-06 1.04 1.00 
Pdlim1 -1.34 0.78 -1.40 0.94 -1.88 8.15E-03 
Per1 1.17 0.30 -1.54 1.84E-14 -1.31 0.13 
Polr2a -1.13 0.92 -1.01 1.00 -1.14 0.03 
Ppm1d 1.22 0.37 -1.33 3.47E-03 -1.09 0.93 
Ptms 1.03 0.84 1.05 0.48 1.08 4.63E-03 
Retsat -1.14 0.26 -1.27 1.20E-03 -1.44 2.59E-10 
Rgs2 1.31 0.24 -1.50 4.79E-04 -1.14 0.93 
Rgs5 -1.18 0.96 -1.24 0.96 -1.47 2.52E-06 
Rif1 1.24 0.39 -1.59 2.02E-04 -1.28 0.16 
Rnf11l1 -1.25 0.40 1.38 0.04 1.10 0.93 
Rpl17 1.20 0.94 -1.36 5.49E-03 -1.13 1.00 
Rtn3 1.03 1.00 -1.09 6.97E-04 -1.06 0.94 
Sec62 1.07 0.97 -1.19 0.04 -1.11 0.93 
Sertad1 1.03 1 -1.93 0.03 -1.87 0.69 
Sfrs11 1.10 0.92 -1.12 0.01 -1.02 1.00 
Sgsm1 1.14 0.59 1.11 0.77 1.26 1.84E-05 
Sh3bgrl 1.03 0.98 -1.15 0.03 -1.11 0.63 
Sik1 1.52 0.7 -2.53 4.77E-03 -1.67 0.37 
Sik2 1.09 0.69 -1.29 1.79E-04 -1.19 0.12 
Ska3 1.20 0.49 1.06 0.97 1.28 0.04 
Slc25a25 1.29 0.06 -2.03 2.49E-09 -1.57 1.61E-06 
Slc25a31 1.28 0.92 -2.42 0.03 -1.88 0.34 
Slc6a6 -1.10 0.97 1.20 1.08E-04 1.09 0.97 
Slx4 -1.15 0.42 1.29 9.05E-04 1.12 0.68 
!Spin1 1.35 0.92 -1.58 3.30E-07 -1.16 1.00 
Spred1 1.13 0.96 -1.29 1.50E-03 -1.14 0.98 
Sprr1a 1.20 1.00 3.81 0.03 4.59 0.01 
Ssfa2 -1.10 0.92 -1.14 0.85 -1.25 0.04 
Stat4 -1.27 0.77 -1.46 0.46 -1.87 3.06E-03 
Syt5 1.18 0.49 1.02 1.00 1.20 2.08E-04 
Tac1 1.06 1.00 -1.59 3.46E-16 -1.50 0.93 
Tiparp 1.07 0.99 -2.04 8.86E-08 -1.92 1.81E-10 
Tmem47 1.15 0.05 -1.16 3.18E-04 -1.01 1.00 
Tmem65 -1.14 0.74 -1.11 0.94 -1.26 8.15E-03 
Tns1 -1.21 0.87 -1.10 0.99 -1.34 3.59E-03 
Tp53inp2 -1.38 0.80 -1.06 1.00 -1.46 0.03 
Tpm1 1.21 0.28 1.03 1.00 1.25 0.03 
Trak1 -1.05 0.98 -1.18 3.02E-03 -1.12 0.93 
Trim9 -1.15 0.97 1.11 7.15E-04 -1.03 1.00 
Txnl4b 1.25 0.74 1.24 0.81 1.55 0.02 
Tyw5 1.39 0.05 -1.46 3.61E-04 -1.05 1.00 
Zbtb16 1.09 1.00 -1.52 3.69E-04 -1.39 0.93 
Zdbf2 1.07 0.99 -1.50 1.96E-05 -1.41 0.15 
Zfp36 1.43 0.34 -1.98 0.03 -1.38 0.93 
 
